Imukin (Recombinant Human Interferon Gamma 1b)

Interferon gamma‑1b binds to the interferon‑γ receptor on immune cells, triggering the JAK‑STAT signaling pathway. This activation increases expression of genes that enhance macrophage killing ability, improve antigen presentation, and promote a Th1‑type immune response, thereby correcting functional deficits in host defense and supporting hematopoiesis.

The dosage of Imukin is individualized by the prescribing clinician based on the specific indication, patient weight, and clinical response. Dosing regimens are established in the product labeling and should be followed exactly as directed by a qualified healthcare professional.

Safety data for Imukin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss individual risk factors and consider alternative therapies when appropriate.

To request Imukin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Imukin is a recombinant cytokine that specifically activates the interferon‑γ pathway, whereas many other immunomodulators, such as interleukin‑2 or monoclonal antibodies, target different receptors or cytokines. This distinct mechanism makes Imukin particularly effective for conditions like CGD and osteopetrosis, where enhancing macrophage function is essential.

Imukin must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport is critical to preserve product stability.

Imukin is supplied as a sterile solution for subcutaneous injection. The injection is typically given by a healthcare professional or trained caregiver, following aseptic technique. The injection site is rotated to minimize local irritation, and patients are observed for any immediate reactions.

Serious risks include severe allergic reactions such as anaphylaxis, autoimmune hepatitis, significant hematologic abnormalities like neutropenia, and pulmonary complications such as edema. Patients should be monitored closely for these events, and any signs of severe reaction require immediate medical attention.

Imukin is contraindicated in individuals with known hypersensitivity to interferon gamma‑1b or any excipients in the formulation. Caution is advised for patients with uncontrolled autoimmune disease, severe hepatic impairment, or those receiving live vaccines. The prescribing clinician must evaluate each patient’s medical history before initiating therapy.